Endotis reports the successful completion of Phase I clinical trials of neutralizable anticoagulant EP217609 and antidote avidin
EP217609 is a first-in-class synthetic, parenteral anticoagulant which can be neutralized with a specific antidote (avidin - an egg-derived protein). It has a dual mechanism of action which combines indirect factor Xa inhibition and direct thrombin inhibition. EP217609 is the neutralizable version of EP42675, which has already successfully completed a Phase I program in 108 healthy subjects.
EP217609 was well tolerated in 24 healthy subjects exposed to single, ascending doses. As expected, administration of the EP217609 anticoagulant resulted in dose-dependent increases in standard and specific coagulation tests, whereas a decrease in thrombin generation was observed. EP217609 ‘s pharmacodynamic and pharmacokinetic profiles were predictable, with low inter-subject variability. In a separate trial, avidin was well tolerated in 24 healthy subjects exposed to single, ascending doses. There was no evidence of hypersensitivity reactions.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.